Jan 26, 2026 Weekly Roundup

Weekly Funding Roundup:
Jan 19–25, 2026

A quieter week after January's mega-rounds. Two notable deals totaling $75M, with capital flowing into AI infrastructure enablers and medtech diagnostics rather than headline-grabbing billion-dollar rounds.

$75M
Total Raised
2
Rounds
117
Global Deals

Key Themes

Volume up, dollars down. Global deal count rose 23% week-over-week to 117 disclosed rounds, but aggregate capital dropped ~76% to $7.17B, a natural digestion period after the mega-rounds of early January (xAI's $20B, Skild AI's $1.4B, Etched's $500M). The market is distributing bets more broadly rather than concentrating in blockbusters.

AI infrastructure enablers gaining attention. Accelsius's $65M for liquid cooling reflects a growing thesis: as AI compute demand surges, the picks-and-shovels layer (cooling, power, networking) becomes a critical bottleneck. Corporate strategics like Johnson Controls and Legrand are positioning early.

Medtech and biotech steady amid AI dominance. While AI captured 57% of January's total capital, healthcare-focused companies like Aclarion continue to raise, especially at the intersection of AI and clinical diagnostics. The sector shows resilience with selective investor interest in evidence-backed platforms.

The Rounds

Accelsius Series B
Jan 12
$65M

The Austin-based liquid cooling startup closed a $65M Series B to scale its NeuCool platform for gigawatt-class AI data centers. Accelsius's two-phase, direct-to-chip cooling handles over 4,500W per socket using safe dielectric refrigerants, a critical enabling technology as GPU power consumption skyrockets. Both lead investor Johnson Controls and Legrand are strategic corporates with deep data center infrastructure reach.

Johnson Controls (Lead) Legrand
Aclarion Equity Raise
Jan 13
$10M

The publicly traded medtech company (NASDAQ: ACON) raised $10.4M through a common stock offering to fund its CLARITY clinical trial and extend its cash runway into 2028. Aclarion's Nociscan platform uses AI-enhanced MRI biomarkers to noninvasively identify the source of chronic low back pain, a condition affecting tens of millions that currently lacks reliable diagnostic tools.

Methodology

Data sourced from company announcements, press coverage, and social media posts via Grok analysis of X. All rounds include linked sources in our database. Source URLs are stored in each company's funding history. Visit individual company pages to see them.

All posts Browse companies